Scarica l'app Stockscreener
1,063.56
1.99%
-21.63
Dopo l'orario di chiusura:
1064.45
0.89
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in - TechStock²
Boston-based Aktis, backed by Eli Lilly, jumps 24% after $318 million US IPO - The Boston Globe
Eli Lilly-Backed Aktis Jumps 24% After $318 Million US IPO - Bloomberg.com
Chai Discovery’s commercial strategy takes shape with Lilly deal - FirstWord
Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences - FinancialContent
Eli Lilly and Company Stock (LLY) Opinions on Obesity Drug Partnership and Acquisition Talks - Quiver Quantitative
Lilly partner Aktis surges on trading debut (AKTS:NASDAQ) - Seeking Alpha
Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery - 01net
Zepbound And Taltz Combo Bolsters Lilly’s Co-Morbidity Plans - Citeline News & Insights
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY) - FinancialContent
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models - PharmiWeb.com
Here's What UBS Thinks About Eli Lilly and Company (LLY) - Finviz
Here’s What UBS Thinks About Eli Lilly and Company (LLY) - Yahoo Finance
Aktis breaks IPO ice with $318M Lilly-led offering - FirstWord
Schrodinger to offer Eli Lilly's AI drug discovery platform on its software - Reuters
Revvity, Inc. Collaborates with Eli Lilly and Company to Expand Access to Ai Drug Discovery Models - MarketScreener
Lilly joins Schrödinger, Revvity for AI drug discovery (update) - Seeking Alpha
Tax agreement for $6.5B Eli Lilly plant is official, including 6-figure average annual wages - The Business Journals
Eli Lilly’s stark new ad takes aim at public judgment around obesity - Ad Age
Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight - Benzinga
Eli Lilly joins Schrödinger in AI drug discovery (SDGR:NASDAQ) - Seeking Alpha
Rx Rundown: Insilico Medicine, Sanofi, Eli Lilly and more - Medical Marketing and Media
Eli Lilly (LLY) Partners with Schrodinger to Enhance Drug Discov - GuruFocus
Big pharma opens its AI drug tools to smaller biotechs in new deal - Stock Titan
Schrödinger partners with Lilly TuneLab to enhance drug discovery By Investing.com - Investing.com Australia
Exclusive: With new AI deal, Eli Lilly and Chai Discovery kick off a 'year of deployment' in pharma - Endpoints News
Eli Lilly: Incretin-Driven Above-Peer Growth Justifies Premium Valuation and Supports Overweight Rating - TipRanks
Eli Lilly vs. Novo Nordisk: Which Is the Best Stock to Buy Today? - Morningstar
Bull of the Day: Eli Lilly (LLY) - Finviz
Eli Lilly and JD.com have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Alveus Therapeutics annoncerer serie A-financiering på 160 mio. USD til næste generations behandlinger mod fedme og stofskiftesygdomme - GlobeNewswire Inc.
Lilly To Buy Ventyx Biosciences For $1.2 Billion To Expand Oral Inflammation Pipeline - Pulse 2.0
Eli Lilly-Backed Aktis Oncology Gets $317.7 Million in US IPO - Bloomberg.com
Major Eli Lilly Stakeholder Makes Bold Move With Massive Share Sale - TipRanks
Ventyx’s NLRP3 inhibitors best in class? Lilly offers $1.2B - BioWorld MedTech
Lilly Endowment sells Eli Lilly & Co (LLY) stock worth $322m - Investing.com India
Pharmacy XD Launches Nationally Licensed Direct-to-Patient Mail Order Pharmacy and Distribution Platform - Benzinga
Lilly Endowment sells Eli Lilly & Co (LLY) stock worth $322m By Investing.com - Investing.com Canada
2 Firms Guide Eli Lilly's $1.2B Ventyx Biosciences Acquisition - Law360
Lilly Endowment Sells Over $322 Million of Eli Lilly & Co Common Stock - TradingView — Track All Markets
Lilly Endowment (LLY 10% owner) discloses Eli Lilly share sales around $1,100 - Stock Titan
Eli Lilly's (LLY) Taltz and Zepbound Show Positive Results in Ps - GuruFocus
Eli Lilly (LLY) Reports Positive Results with Psoriatic Arthritis Treatment - GuruFocus
Lilly trial finds psoriatric arthritis, weight improvement in Taltz + Zepbound combo - Seeking Alpha
Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial - Reuters
Eli Lilly (LLY) Poised for Aggressive M&A Amid Biopharma Surge - GuruFocus
Lilly’s taltz and zepbound combination shows efficacy in psoriatic arthritis - Investing.com
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight - Eli Lilly
Lilly touts promise of Zepbound-Taltz combo in patients with obesity and psoriatic arthritis - Fierce Pharma
Lilly’s Zepbound Plus Arthritis Drug Taltz Eases Joint Pain - Bloomberg.com
Biopharma stocks to see increased M&A activity amid Eli Lilly-Ventyx deal (IBB:NASDAQ) - Seeking Alpha
Lilly buys Ventyx in $1.2bn deal to tackle chronic inflammation - BioXconomy
Eli Lilly stock rises as Bernstein reiterates Outperform rating By Investing.com - Investing.com Canada
Lilly to acquire Ventyx Biosciences stock for $14 per share - Investing.com
Lilly to acquire Ventyx Biosciences stock for $14 per share By Investing.com - Investing.com UK
Eli Lilly stock to acquire Ventyx for $1.2 billion, Cantor Fitzgerald maintains Overweight rating - Investing.com
ClearBridge Large Cap Growth Strategy’s Thoughts on Eli Lilly and Company (LLY) - Insider Monkey
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn - Pharmaceutical Technology
Dow Drops, Eli Lilly Rockets — And Google Quietly Beats Apple at Its Own Game - Eudaimonia and Co
Lilly to acquire California-based biopharma company in $1.2B deal - Inside INdiana Business
Eli Lilly completes billion-dollar acquisition of US biotech company - medwatch.com
Eli Lilly to acquire Ventyx Biosciences stock for $1.2 billion as Clear Street downgrades - Investing.com
UBS downgrades Ventyx Biosciences stock to Neutral on Eli Lilly acquisition - Investing.com UK
Eli Lilly Shares Surge on Strategic Expansion in Metabolic Therapeutics - AD HOC NEWS
Eli Lilly (LLY) Acquires Ventyx Biosciences for $1.2 Billion - GuruFocus
0.66%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):